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ABSTRACT: Stereoselective biocatalysis by crotonase superfamily enzymes is exemplified by use of engineered 5-carboxymethylproline syn-
thases (CMPSs) for preparation of functionalized 5-carboxymethylproline (5-CMP) derivatives methylated at two positions (i.e. C2/C6, 
C3/C6 and C5/C6), including products with a quaternary centre, from appropriately-substituted-amino acid aldehydes and C-2 epimeric 
methylmalonyl-CoA. The enzymatically-produced disubstituted 5-CMPs were converted by carbapenam synthetase into methylated bicyclic 
β-lactams, which manifest improved hydrolytic stability compared to the unsubstituted carbapenams. The results highlight the use of modified 
carbapenem biosynthesis enzymes for production of new carbapenams with improved properties.  
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Although resistance to them is growing, the β-lactams remain the 
most important antibacterials.1 The carbapenems, which are often 
the most effective β-lactams from a clinical perspective, are pro-
duced by total synthesis, normally rendering them more expensive 
than penicillins and cephalosporins, which are derived from fer-
mented products. This ‘cost of goods’ issue has limited clinical stud-
ies on carbapenem variants. Structure activity relationship (SAR) 
studies, on carbapenems2 and other β-lactam antibacterials, reveal 
that the nature and pattern of substitution of the bicyclic system 
modulates antibacterial activity, resistance to hydrolysis by β-lac-
tamases and other enzymes (e.g. renal dehydropeptidases3-4), and 
non-enzymatic hydrolytic stability.5 We have thus been exploring 
the scope of engineered carbapenem biosynthesis enzymes for the 
biocatalytic synthesis of bicyclic β-lactam antibacterials, β-lactam 
based inhibitors of other targets,6-8 and of proline derivatives for use 
in catalysis.9-10  
Three enzymes, CarB, CarA, and CarC,11-12 are directly responsible 
for the biosynthesis of the simplest carbapenem, (5R)-carbapen-2-
em-3-carboxylate, in Pectobacterium carotovorum. In contrast mul-
tiple  enzymes are involved in the assembly of the C2/C6-disubsti-
tuted carbapenem thienamycin in Streptomyces cattleya, making 
the engineering of this pathway more challenging (Fig. 1A).2,13 In 
both cases, a 5-membered β-amino acid carbapenam precursor is in-
itially constructed as catalysed by a member of the crotonase super-
family:14 CarB in P. carotovorum15-18 and ThnE in S. cattleya.19-20 
These crotonases catalyse the selective transformation of malonyl-
CoA and an equilibrating mixture of (2S)-glutamate semialde-
hyde/5-hydroxyproline/pyroline-5-carboxylate (collectively (2S)-
GHP) into (2S,5S)-5-carboxymethylproline (t-CMP)) (Fig. 1A). 
CarB/ThnE catalysis proceeds via malonyl-CoA decarboxylation to 
give an enzyme-bound acetyl-CoA enolate that is likely stabilized by 
an oxy-anion hole, which is formed by two residues in the active site 
of the carboxymethylproline synthases (CMPSs) (Fig. 1B). C-C 
bond formation then proceeds via nucleophilic attack of the enolate 
on the (Re)-face of the iminium form of pyroline-5-carboxylate. 
Subsequent hydrolysis of the resultant thioester intermediate gives 
t-CMP and CoASH (Fig. 1A).15-16 The ATP and MgII-dependent β-
lactam synthetase CarA in P. carotovorum (and likely ThnM in S. 
cattleya) then catalyzes cyclisation of t-CMP into (3S,5S)-carbape-
nam-3-carboxylate ((3S,5S)-C3C), Fig. 1A.20-21 While the en-
zyme(s) catalyzing C-5 epimerization   and C-2/C-3 desaturation 
are yet to be defined in thienamycin biosynthesis;2 in P. caroto-
vorum, the 2-oxoglutarate and FeII-dependent oxygenase CarC cat-
alyzes formation of (5R)-carbapen-2-em-3-carboxylate from 
(3S,5S)-C3C (Fig. 1A).22-23 
We have described the use of CarB and ThnE variants to catalyse 
production of singly alkylated t-CMP derivatives, at either C-2 or C-
6 from the appropriate (2S)-GHP and malonyl-CoA derivatives.15,24-
26 We now report on the use of engineered CMPSs to catalyse the 
stereoselective preparation of disubstituted CMP derivatives, in-
cluding some with a quaternary carbon, from appropriately-substi-
tuted amino-acid aldehydes and C-2 epimeric methylmalonyl-CoA. 
The potential utility of the method is demonstrated by conversion 
of the products into bicyclic β-lactams using CarA catalysis. 
Preparation of (2,6)-dimethyl-t-CMP derivatives: We began by test-
ing the capacity of reported CMPS variants24-28 to catalyse formation 
of 2,6-dimethyl-t-CMP derivatives (Scheme 1I). The selection of 
CMPS variants for testing for production of dimethylated-t-CMP 
derivatives was guided by earlier studies revealing that certain CMPS 
variants manifest relaxed substrate selectivity, e.g. CarB H229A for 
construction of 2-methyl-substituted t-CMP derivatives.25  
Incubation of racemic (2S/2R)-2-methyl-GHP25 and C-2 epimeric 
methylmalonyl-CoA with CarB H229A (the highest yielding CMPS 
variant identified for this transformation), followed by LC-MS anal-
ysis resulted in observation of two species, both with the predicted 
mass for the epimeric dimethylated products (m/z = 202.1 
[M+1]+). The ratio between the two C-6 epimers observed was ~ 
63:37 (as observed by LC-MS and NMR analyses).  Scale-up and 
LC-MS guided purification led to the isolation (>95% pure by 1H-
  
Figure 1. Carbapenem biosynthesis. A: Roles of the enzymes utilized in this study in the biosynthesis of (5R)-carbapenem-3-carboxylic acid (i.e. CarB 
and CarA in Pectobacterium carotovorum) and thienamycin (i.e. ThnE, in Streptomyces cattleya).2 Note that many clinically used carbapenems are 
substituted at C-1 and are always substituted at C-2 and C-6, sometimes forming a tricyclic system (insert, X = sulfur or carbon); B: View from a crystal 
structure of CarB18 with malonyl-CoA and (2S)-pyrroline-5-carboxylate (P5C) modeled into the active site, highlighting some of the active site resi-
dues, which were substituted in the variants used in this study (the analogous ThnE residues are shown in blue).19 
NMR, Fig. 2A and B) of the two C-6 epimers that were character-
ised by 2D NMR analyses (Figs. S1 and S2). The NMR analyses 
revealed the first and second eluting epimers to have the (2S,6S)- 
and (2S,6R)-stereochemistry, respectively. In contrast, with the 
available set of CMPS variants (Table S1), use of C-2 epimeric 
ethylmalonyl-CoA19 and 2-methyl-GHP did not result in detecta-
ble t-CMP derivatives (by LC-MS analysis). Notably, the other 
CarB/ThnE variants tested (Table S1) were unable to catalyse for-
mation of the 2,6-dimethyl-t-CMP epimers at appreciable levels 
(<5% by LC-MS analysis).  
These results demonstrate the ability of CarB H229A to catalyse 
formation of 2,6-dimethyl-t-CMP derivatives with adjacent ter-
tiary stereocentres (at C5 and C6), in addition to the preinstalled 
and sterically-demanding quaternary centre (at C2), in a single 
transformation and in moderate unoptimised isolated yield (28% 
from racemic (2S/2R)-2-methyl-GHP, Table 1, entry 1). The ca-
pacity of CarB H229A to accept substrate analogues with a  qua-
ternary C-2 stereocentre is likely due to increased active site vol-
ume in the region binding C-2  as implied by crystallographic stud-
ies18 (Fig. 1B). 
Scheme 1. Products of CMPS catalysis resulting from incubation of C2-, C3-, and C5-methylated-(2S)-GHP derivatives with C-2 epimeric 
methylmalonyl-CoA.  
 
A potential product that was not observed, within limits of detection, is in grey. The GHP derivatives (in the case of I, II and III) were prepared as 
racemates, but only compounds with the (2S)-stereochemistry are known to be CMPS susbtrates.19,25,29
  
Figure 2. Production of dimethyl-substituted-t-CMP derivatives with quaternary stereocentres. A, B and C: 1H-NMR spectra for the shown dimethyl-
substituted-t-CMP epimers resulting from incubation of C-2 epimeric methylmalonyl-CoA and racemic 2-methyl-GHP (A and B)/(2S)-5-methyl-
GHP (C), as catalyzed by CarB H229A (A and B)/ThnE W124F/V153M (C), respectively; D: View from a model of ThnE V153A variant active site 
based on structures of wildtype CarB18  with (R)-methylmalonyl-CoA and (2S)-5-methyl-P5C substrate analogues modelled at the active site. The 
selectivity of ThnE V153A variant for production of the (5S,6S)-5,6-dimethyl-t-CMP epimer can be rationalized by a steric clash between the methyl 
group of the (Z)-enolate resulting from decarboxylation of (S)-methylmalonyl-CoA and the methyl group of (2S)-5-methyl-P5C.  during the C-C 
bond formation; E: View from a ThnE model with (R)-methylmalonyl-CoA and (2S)-P5C substrate in the active site. Note the potential for a steric 
clash between the methyl group of methylmalonyl-CoA and Val-153, which rationalizes preferential production of the (6R)- epimers by ThnE and 
ThnE variants with a β-branched amino acid at residue-153 (e.g. ThnE V153I). Note that the lack of such clash in D rationalizes for the preferential 
production of epimers with (6S)-stereochemistry by ThnE and ThnE variants without a β-branched amino acid at position 153 (e.g. ThnE V153A). 
Preparation of (3,6)-dimethyl-t-CMP derivatives: We then inves-
tigated preparation of 3,6-dimethyl-t-CMP derivatives, because 
many natural and synthetic carbapenems are substituted at bicyclic 
ring positions analogous to C-3 and C-6 of t-CMP (Figure1A).2 
Incubation of C-2 epimeric methylmalonyl-CoA and a racemic 
mixture of  (2S,3S)-/(2R,3R)-3-methyl-GHP (only GHP sub-
strates with the (2S), but not (2R)-, stereochemistry are accepted 
by CarB, ThnE and variants thereof)19,25,29 with wildtype or engi-
neered CMPS variants resulted in the observation (by LC-MS) of 
two products with the anticipated mass (m/z = 202.1 [M+1]+) 
(Fig. 3, Scheme 1II). Interestingly, the ThnE/ThnE-variants man-
ifested different patterns of stereoselectivity towards production of 
the two observed C-6 epimers of 3,6-dimethyl-t-CMP, compared 
to the CarB/CarB-variants (Fig. 3, Table S2). Wildtype CarB pro-
duced the highest relative yield of the first eluting epimer (31%, 
Table S2, entry 1); however, wildtype ThnE (Table S2, entry 2) 
and the ThnE V153I variant (Table 1, entry 2) produced the high-
est diastereomeric excess (d.e.) of the same epimer (d.e. = 0.86, in 
the case of the ThnE V153I variant). Whilst the ThnE V153L var-
iant produced the highest relative yield of the later-eluting epimer 
(~42%, Table 1, entry 3), the ThnE V153A variant produced the 
highest d.e. of the same epimer with a comparative yield (d.e., in 
the case of ThnE V153A, = 0.80, Table S2, entry 9). Following LC-
MS-guided purification of the scaled-up preparation, NMR inves-
tigations of the major product of ThnE V153I catalysis revealed its 
stereochemistry as (2S,3S,6R) (Figs. 3, S3 and S4, assuming con-
version of the (2S)-substrate).19,25,29 The major product of ThnE 
V153L catalysis was shown to be the (2S,3S,6S)-stereoisomer 
(Figs. 3, S3 and S5). The comparatively low yields in the case of 
ThnE W124F, ThnE W124F/V153M, and ThnE H274A variants 
(Table S2, entries 4-6, respectively) may reflect a slower rate of hy-
drolysis of the t-CMP-CoA thioester intermediate by these vari-
ants (Fig. S6). Preliminary evidence for the slower rate of such hy-
drolysis originates from the observation of a species with m/z = 
216.1 (Figs. S6A and C), in the total ion chromatograms of these 
variants, corresponding to the methyl ester of 3,6-dimethyl-t-
CMP, which we have proposed to be produced by methanolysis of 
the (normally enzyme-bound) thioester intermediate which leaks 
from the active site16 before or during methanol quenching of the 
reaction (Fig. S6D).24 
Incubation of racemic (2S,3R)-/(2R,3S)-3-methyl-GHP25 and C-
2 epimeric methylmalonyl-CoA with wildtype and engineered 
CMPS variants resulted in the observation of two LC-MS peaks 
with the anticipated mass (m/z = 202.1 [M+1]+) (Fig. 3, Scheme 
1III and Table S3). Whilst CarB M108I produced the highest rel-
ative yield and d.e. of the first epimer to elute (~29% at d.e. = 0.06, 
Table 1, entry 4), ThnE V153L (Table S3, entry 8) and CarB 
W79A (Table 1, entry 5) produced the highest relative yield and 
diastereomeric excess of the later-eluting epimer (~44% at d.e. = 
0.94, in the case of CarB W79A). Subsequent analyses identified 
the major product of CarB M108I catalysis as the (2S,3R,6R)-ste-
reoisomer (Figs. 3 and S7) and the major product of CarB W79A 
catalysis as the (2S,3R,6S)-stereoisomer (Figs. 3 and S8). Note 
that the stereochemical assignments of disubstituted-t-CMP mon-
ocycles are supported by analyses on the corresponding bicyclic β-
lactams (see below).  
Incubation of C-2 epimeric ethylmalonyl-CoA19 with either of the 
(2S)-3-methyl-GHP isomers did not result in the formation of t-
CMP derivatives at appreciable (>5%) levels with any of the 
CMPSs tested, except for the CarB W79F and CarB W79A vari-
ants. LC-MS analyses revealed that these variants catalyse the for-
mation of 6-ethyl-3-methyl-t-CMP diastereomers in yields ranging 
from 6 to 14% (Fig. S9). The strong preference of the CarB W79A  
 Table 1. N-Heterocycles resulting from incubation of C-2, C-3 and C-5 methylated-(2S)-GHP with C-2 epimeric methylmalonyl-CoA as cat-
alysed by the preferred engineered CMPS variants, in terms of yield and/or diastereomeric excess. 
 
Entry Catalyst (2S)-GHP Substrate Product(s) d.r.a %Yieldb 
1 CarB H229A R1 = CH3 R1= R5= CH3 63 14 (28) 
R1= R6= CH3 37 
2 ThnE V153I R2 = CH3 R2= R6= CH3 93 12 (23)b,c 
R2= R5= CH3 07 
3 ThnE V153L R2 = CH3 R2= R6= CH3 14 25 (49)b,c 
R2= R5= CH3 86 
4 CarB M108I R3 = CH3 R3= R6= CH3 53 27 (54) b,c 
R3= R5= CH3 47 
5 CarB W79A R3 = CH3 R3= R6= CH3 03 22 (45)b,c 
R3= R5= CH3 97 
6 ThnE W124F/V153M R4 = CH3 R4 = R5= CH3 >99:1 17 
a  d.r.= diastereomeric ratio of C-6 epimers of t-CMP derivatives with a methyl substituent at C-2, C-3 and C-5, as determined by 1H NMR spectroscopy 
and/or LC-MS analyses, under standard incubation conditions. b The % yield (isolated, rounded numbers) was calculated over the following steps:25-
26,28 deprotection of amino acid aldehydes, incubation with enzyme(s), LC-MS (double) purification, and (double) lyophilization; products were quan-
tified by 1H NMR using [2H]4-trimethylsilylpropionate as a standard. c Starting materials in the case of entries 1-5 were prepared as racemates; yields, 
taking this into account, are in parentheses. R=H may be assumed, unless otherwise stated. 
 
Figure 3. Ion-extracted LC-MS chromatograms (ESI+, m/z = 202.1), yields and diastereomeric ratios for the two C-6 epimers of (3S)-3,6-dimethyl-t-
CMP (left) and those of (3R)-3,6-dimethyl-t-CMP (right) obtained by incubation of C-2 epimeric methylmalonyl-CoA and racemic (2S,3S)-3-me-
thyl-GHP or racemic (2S,3R)-3-methyl-GHP, respectively, as catalysed by CMPS variants, under standard conditions. Only the preferred engineered 
CMPS variants, in terms of yield and/or diastereomeric excess, are presented. 
 variant for products with the (6S)-stereochemistry was largely 
maintained when racemic (2S,3R)-3-methyl-GHP and C-2 epi-
meric ethylmalonyl-CoA were used as co-substrates (d.e. = 0.94, 
Fig. S9). Coupling of crotonyl-CoA carboxylase/reductase (Ccr) 
catalysis, which exclusively produces (2S)-ethylmalonyl-CoA,30 to 
that of CarB W79F,24,26 was employed to conclusively assign the C-
6 stereochemistry of the resulting 6-ethyl-3-methyl-t-CMP dia-
stereomers (Fig. S10). 
Preparation of (5,6)-dimethyl-t-CMP derivatives: Many alkaloids 
contain a substructure comprising a 5-membered N-heterocycle 
with a quaternary centre, and possess a wide range of biological ac-
tivities (e.g. physostigmine).31 The possibility of stereocontrol by 
CMPS catalysis with adjacent stereocentres was thus evaluated 
employing C-5 epimeric (2S)-5-methyl-GHP (i.e. a mixture of 
(2S,5R)- and (2S,5S)-5-methyl-GHP) and C-2 epimeric 
methylmalonyl-CoA (Scheme 1IV). LC-MS analyses revealed a 
single chromatographic peak with the anticipated mass (m/z 
=202.1 [M+1]+), as catalysed by wild-type ThnE, ThnE V153A or 
ThnE W124F/V153M only (Fig. S11). 
ThnE W124F/V153M was the highest yielding variant; the rela-
tive yields of wild-type ThnE and ThnE V153A were 6% and 68%, 
respectively (Fig. S11). Following, scaled-up preparation, guided 
by LC-MS, 2D NMR analysis of the product of ThnE 
W124F/V153M -catalysis revealed that the product formed is ex-
clusively the (2S,5S,6S)-5,6-dimethyl-CMP stereoisomer, with no 
evidence for formation of any other of the three possible stereoiso-
mers, including the (2S,5S,6R) epimer (Scheme 1IV, Table 1, en-
try 6, Figs. 1, S12 and S13). When C-2 epimeric ethylmalonyl-CoA 
was incubated with (2S)-5-methyl-GHP, no CMP derivative was 
detected, by LC-MS, with any of the tested CMPSs.  
Overall, these results reveal the capacity of CMPS variants to cata-
lyse the stereocontrolled generation of contiguous, tertiary and 
heteroatom-substituted quaternary, stereocentres in a single trans-
formation (in ~17% isolated yield and >0.99 d.e. in the case of 
ThnE W124F/V153M). 
Conversion of t-CMP derivatives into bicyclic β-lactams: We then 
investigated conversion of the dimethyl-substituted-t-CMP deriv-
atives to bicyclic β-lactams using the synthetase CarA (Fig. 1A). 
CarA efficiently catalysed the conversion of five out of the seven 
prepared dimethyl-substituted-t-CMP derivatives tested (75-
100%), as demonstrated by LC-MS and (2D) NMR analyses (Ta-
ble 2 and Figs. 4, S14-S22). The results reveal that dimethyl-sub-
stituted-t-CMP diastereoisomers with the (6S)-stereochemistry 
are less favored CarA substrates compared to the (6R)-epimers 
(compare entries 1, 3 and 5 with entries 2, 4, 6 and 7, Table 2), 
likely due to steric constraints (Fig. 4D/E). Indeed, in the cases of 
two disubstituted-t-CMP derivatives with the(6S)-stereochemis-
try (i.e. (2S,6S)-2,6-dimethyl-t-CMP and (5S,6S)-5,6-dimethyl-t-
CMP), no evidence for CarA catalysed bicyclisation was accrued, 
under the tested conditions (Table 2, entry 2 and 7). The conver-
sion of the reported t-CMP derivatives to bicyclic β-lactams ena-
bled more definitive assignment of the C-6 stereochemistry, which 
is difficult in the monocyclic t-CMP derivatives due to rotation 
about the C5-C6 bond. Whilst diastereomers with the (6S)-stere-
ochemistry manifested a J5,6 = 1.6-1.8 Hz, which is typical for β-
lactams with H5 and H6 in a trans-relationship (Figs. S20 and 
S22), those with the (6R)-stereochemistry manifested a J5,6 = 4.8- 
 
Figure 4. Preparation of dimethyl-substituted carbapenam-3-carboxylic acids by CarA catalysis. A-C: 1H NMR spectra of the 3,6-dimethyl-substituted 
carbapenam-3-carboxylic acids prepared from 3,6-dimethyl-t-CMP derivatives (Table 2) employing CarA (For more examples, see Figs. S15 and S20); 
D and E: Views from a CarA crystal structure (PDB 1Q19)32 with the acyl-adenylate intermediate of the C-6 epimers of 2,6-dimethyl-t-CMP modelled 
in the active site. Note that the intramolecular Bürgi-Dunitz trajectory for nucleophilic attack of the secondary amine on the carbonyl of the acyl-
adenylate appears less sterically hindered for the (6R)-epimer (A) compared to the (6S)-epimer (B), rationalizing the preference of CarA for substrate 
epimers with the (6R)-stereochemistry. In both cases, the fold of the acyl-adenylate intermediate is likely to suffer limited conformational space because 
of the bulky substituent at C-2 of the t-CMP nucleus. The model is built on the basis of the acyl-adenylate N2-(2-carboxymethyl)arginine-AMP species 
bound in a crystal structure of β-LS (PDB 1MBZ).33 The Lys443 residue is proposed34 to assist in ring cyclisation via stabilisation of the proposed 
“tetrahedral” intermediate (resulting upon nucleophile attack by the secondary amine of t-CMP). The shown Tyr345-Glu380 dyad is proposed to 
deprotonate the amine involved in the intramolecular β-lactam formation.35
 Table 2. Conversion of disubstituted-t-CMP derivatives into disubstituted-carbapenam-3-carboxylate (C3C) derivatives by carbapenam syn-
thetase (Car A) catalysis. 
 
 
Entry Substrate Product %Conversiona t1/2 (days)b 
1 (2S,6R)-2,6-dimethyl-t-CMP: 
R1 = R6 = CH3 
(3S,5S,6R)-3,6-dimethyl-C3C: 
R1 = R6 = CH3 
75  
2 (2S,6S)-2,6-dimethyl-t-CMP: 
R1 = R5 = CH3 
(3S,5S,6S)-3,6-dimethyl-C3C: 
R1 = R5 = CH3 
0  
3 (3S,6R)-3,6-dimethyl-t-CMP: 
R2 = R6 = CH3 
(2S,3S,5S,6R)-2,6-dimethyl-C3C: 
R2 = R6 = CH3 
100 16 
4 (3S,6S)-3,6-dimethyl-t-CMP: 
R2 = R5 = CH3 
(2S,3S,5S,6S)-2,6-dimethyl-C3C: 
R2 = R5 = CH3 
83 24 
5 (3R,6R)-3,6-dimethyl-t-CMP: 
R3 = R6 = CH3 
(2R,3S,5S,6R)-2,6-dimethyl-C3C: 
R3 = R6 = CH3 
100  
6 (3R,6S)-3,6-dimethyl-t-CMP: 
R3 = R5 = CH3 
(2R,3S,5S,6S)-2,6-dimethyl-C3C: 
R3 = R5 = CH3 
87  
7 (5S,6S)-2,6-dimethyl-t-CMP: 
R4 = R5 = CH3 
(3S,5S,6S)-5,6-dimethyl-C3C: 
R4 = R5 = CH3 
0  
a % conversion was determined by LC-MS analyses. b The time required for half of the carbapenam to decompose; calculated for the shown derivatives 
only, where the purified carbapenam was kept (inside a 2 mm NMR tube) at 4°C in sodium formate pH~7 (as described in the supporting information). 
Hydrolysis was monitored by 1H NMR analyses (e.g., see Fig. S23). R=H may be assumed, unless otherwise stated.
5.3 Hz, which is typical for β-lactams with H5 and H6 in a cis-rela-
tionship (Figs. S15, S18 and S21).36 The simplest (unsubstituted) 
carbapenem, (5R)-carbapenem-3-carboxylate (Fig. 1A) is highly 
unstable, to the extent that its isolation in the free form (rather 
than as ester derivative) has not been possible.37 Indeed only five 
carbapenams2 have been isolated from natural sources, mainly as 
ester derivatives, likely due to instability of the free acids.38-41 Inter-
estingly, some of the disubstituted carbapenams prepared using 
CarA displayed increased resistance to hydrolysis (t1/2 ~16-24 
days, 4°C, in sodium formate buffer pH~7; Table 2, entry 3 and 4, 
and Fig. S23) when compared to their unsubstituted/mono-sub-
stituted counterparts, which, in our hands, almost completely hy-
drolyzed during post-purification lyophilization, as evidenced by 
NMR analyses. 
Discussion: The overall results illustrate the biocatalytic scope of 
CMPS variants for the stereoselective synthesis of dialkylated-t-
CMP derivatives; such compounds are of interest as antibacterial 
precursors and as starting materials for the preparation of β-lac-
tams with other targets, as well as for proline-related organic cata-
lysts. The combined use of the CMPS variants and CarA enables 
the two-step synthesis of densely functionalized bicyclic β-lactams 
from alkyl-malonyl-CoA and (2S)-GHP derivatives. The cost of 
reagents means the present conditions are unlikely to be commer-
cially useful, but there is the possibility of reconstructing pathways 
pioneered with isolated recombinant enzymes in cells. It should 
also be noted that the individual reactions are unoptimized, hence 
there is likely for considerable scope for improved yields, especially 
in cells.  
We hope that the results will promote further work on the con-
struction of hybrid natural/unnatural pathways for the synthesis of 
useful antibacterials, especially carbapenems and related com-
pounds, in a manner that is more complex, but the same in concept 
as that applied very so successfully for the production of clinically 
useful penicillins many decades ago.2 Modern molecular and syn-
thetic biology approaches coupled to structural and mechanistic 
insights should enable construction of more complex pathways 
than the simple, though hugely important, penicillin side-chain ex-
change process.42  
More generally the results further highlight the largely unexplored 
biocatalytic potential of crotonase superfamily enzymes.14,43 In this 
regard, the capability to make compounds with ‘demanding’ qua-
ternary centres is striking. This is exemplified in the ThnE 
W124F/V153M-catalysed reaction of (2S)-5-methyl-GHP and C-
2 methylmalonyl-CoA to give (5S,6S)-5,6-dimethyl-t-CMP. How-
ever, at least for the currently available variants, there are limita-
tions in substrate scope, e.g. we did not observe formation of 
(5S,6R)-5,6-dimethyl-t-CMP, likely due to steric constraints (a 
potential clash between the trisubstituted (Z)-enolate intermedi-
ate, resulting from decarboxylation of (2S)-methylmalonyl-CoA, 
and (2S)-5-methyl-GHP, Fig. 2D). The results reveal that the ste-
ric limitations are not as tight for reactions with the (2S)-3-methyl-
GHP isomers where both C-6 epimers were observed, though var-
ying in ratios depending on the CMPS variant used (Table S2 and 
S3, Fig. 3). We have previously found that CMPS variants with a 
β-branched residue (i.e. Val or Ile) at the oxyanion hole forming 
residue 108CarB (wild-type Met)/153ThnE (wild-type Val) favor the 
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formation of products with the (6R)-stereochemistry,24,26 as is also 
the case with formation of the dialkylated products (e.g. entries 2 
and 3 in Table S2 and entry 3 in Table S3). On the other hand, 
CMPS variants with a non-β-branched residue (Leu, Met, Ala) 
have a bias towards producing the (6S)-epimer of 3,6-dimethyl-t-
CMP (e.g. entries 7–9 in Table S2 and entries 1, 2, 8 and 9 in Table 
S3). These preferences may result from a steric clash between the 
methyl-substituent on the trisubstituted (E)-enolate, resulting 
from (2R)-methylmalonyl-CoA decarboxylation, and the β-
branched residues (Val or Ile) at the oxyanion hole forming resi-
due of tested CMPS variants (Fig. 2E).26 It is also notable that, in 
general, Trp79CarB/Trp124ThnE-based CMPS variants with less 
bulky residues at this position, favor formation of (6S)- epimers  
(entries 4 and 5 in Table S2 and entries 5–7 in Table S3), con-
sistent with earlier reports.24,26 This is likely due, at least in part, to 
provision of more space in a hydrophobic region with conse-
quently  improved accommodation of the (2R)-alkyl group of the 
malonyl-CoA derivative and/or the subsequently formed (E)-
enolate.24,26 
Although CarA engineering/redesign was not our main focus, 
combined with previous reports,21,25,28,44 our results highlight the 
potential of synthetases for stereoselective biocatalysis of β-
lactams.2 Notably, whilst CarA demonstrated a considerable 
degree of promiscuity, not all substrate analogues were converted, 
suggesting scope for structure- and analogue-guided engineering 
to expand the scope of Car A catalysis, including with respect to 
making C-5 alkyl-carbapenams. Since crystal structures of CarA in 
complex with its acyl-adenylate t-CMP intermediate (or analogue 
thereof) are not yet available,32 the substrate analogue studies 
described here may help in mapping the CarA active site topology, 
with the aim of identifying CarA variants for efficient production 
of substituted carbapenams. 
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